methylprednisolone + rituximab

A combination therapy consisting of methylprednisolone (a synthetic glucocorticoid) and rituximab (an anti-CD20 monoclonal antibody). This non-myelosuppressive regimen is primarily used in the treatment of chronic lymphocytic leukemia (CLL), particularly in patients who are refractory to fludarabine-containing regimens or have limited myeloid reserve. The combination has shown high response rates (93-96%) in clinical studies, with complete remission rates of 14-32%. Methylprednisolone is typically administered at high doses (1 g/m² daily for 3-5 days) while rituximab is given at 375 mg/m² on day 1 of treatment cycles.

Other names

HDMP-RHDMP-rituximabhigh-dose methylprednisolone and rituximab